Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Zoetis Inc. net fixed asset turnover ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level. |
Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Zoetis Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level. |
Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Zoetis Inc. total asset turnover ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level. |
Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Zoetis Inc. equity turnover ratio deteriorated from 2019 to 2020 and from 2020 to 2021. |
Net Fixed Asset Turnover
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Revenue | 7,776) | 6,675) | 6,260) | 5,825) | 5,307) | |
Property, plant and equipment, less accumulated depreciation | 2,422) | 2,202) | 1,940) | 1,658) | 1,435) | |
Long-term Activity Ratio | ||||||
Net fixed asset turnover1 | 3.21 | 3.03 | 3.23 | 3.51 | 3.70 | |
Benchmarks | ||||||
Net Fixed Asset Turnover, Competitors2 | ||||||
AbbVie Inc. | 11.00 | 8.73 | 11.23 | — | — | |
Amgen Inc. | 4.69 | 4.96 | 4.51 | — | — | |
Bristol-Myers Squibb Co. | 7.67 | 7.22 | 4.18 | — | — | |
Eli Lilly & Co. | 3.15 | 2.83 | 2.83 | — | — | |
Gilead Sciences Inc. | 5.27 | 4.90 | 4.91 | — | — | |
Johnson & Johnson | 4.95 | 4.40 | 4.65 | — | — | |
Merck & Co. Inc. | 2.53 | 2.67 | 3.11 | — | — | |
Pfizer Inc. | 5.46 | 3.01 | 3.71 | — | — | |
Regeneron Pharmaceuticals Inc. | 4.62 | 2.64 | 2.72 | — | — | |
Thermo Fisher Scientific Inc. | 4.71 | 5.45 | 5.38 | — | — | |
Vertex Pharmaceuticals Inc. | 6.92 | 6.47 | 5.59 | — | — | |
Net Fixed Asset Turnover, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | 4.86 | 4.21 | 4.22 | — | — | |
Net Fixed Asset Turnover, Industry | ||||||
Health Care | 10.38 | 9.62 | 9.72 | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Net fixed asset turnover = Revenue ÷ Property, plant and equipment, less accumulated depreciation
= 7,776 ÷ 2,422 = 3.21
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Zoetis Inc. net fixed asset turnover ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Zoetis Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Revenue | 7,776) | 6,675) | 6,260) | 5,825) | 5,307) | |
Property, plant and equipment, less accumulated depreciation | 2,422) | 2,202) | 1,940) | 1,658) | 1,435) | |
Operating lease right of use assets | 181) | 192) | 189) | —) | —) | |
Property, plant and equipment, less accumulated depreciation (including operating lease, right-of-use asset) | 2,603) | 2,394) | 2,129) | 1,658) | 1,435) | |
Long-term Activity Ratio | ||||||
Net fixed asset turnover (including operating lease, right-of-use asset)1 | 2.99 | 2.79 | 2.94 | 3.51 | 3.70 | |
Benchmarks | ||||||
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
AbbVie Inc. | 9.57 | 7.46 | 10.06 | — | — | |
Amgen Inc. | 4.23 | 4.58 | 4.11 | — | — | |
Bristol-Myers Squibb Co. | 6.66 | 6.30 | 3.76 | — | — | |
Eli Lilly & Co. | 2.93 | 2.63 | 2.66 | — | — | |
Gilead Sciences Inc. | 4.77 | 4.34 | 4.28 | — | — | |
Johnson & Johnson | 4.72 | 4.18 | 4.41 | — | — | |
Merck & Co. Inc. | 2.33 | 2.43 | 2.90 | — | — | |
Pfizer Inc. | 4.59 | 2.74 | 3.39 | — | — | |
Regeneron Pharmaceuticals Inc. | 4.52 | 2.58 | 2.66 | — | — | |
Thermo Fisher Scientific Inc. | 3.98 | 4.82 | 4.69 | — | — | |
Vertex Pharmaceuticals Inc. | 5.32 | 4.83 | 5.00 | — | — | |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | 4.37 | 3.84 | 3.89 | — | — | |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry | ||||||
Health Care | 8.22 | 7.54 | 7.63 | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property, plant and equipment, less accumulated depreciation (including operating lease, right-of-use asset)
= 7,776 ÷ 2,603 = 2.99
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Zoetis Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level. |
Total Asset Turnover
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Revenue | 7,776) | 6,675) | 6,260) | 5,825) | 5,307) | |
Total assets | 13,900) | 13,609) | 11,545) | 10,777) | 8,586) | |
Long-term Activity Ratio | ||||||
Total asset turnover1 | 0.56 | 0.49 | 0.54 | 0.54 | 0.62 | |
Benchmarks | ||||||
Total Asset Turnover, Competitors2 | ||||||
AbbVie Inc. | 0.38 | 0.30 | 0.37 | — | — | |
Amgen Inc. | 0.40 | 0.39 | 0.37 | — | — | |
Bristol-Myers Squibb Co. | 0.42 | 0.36 | 0.20 | — | — | |
Eli Lilly & Co. | 0.58 | 0.53 | 0.57 | — | — | |
Gilead Sciences Inc. | 0.40 | 0.36 | 0.36 | — | — | |
Johnson & Johnson | 0.52 | 0.47 | 0.52 | — | — | |
Merck & Co. Inc. | 0.46 | 0.52 | 0.55 | — | — | |
Pfizer Inc. | 0.45 | 0.27 | 0.31 | — | — | |
Regeneron Pharmaceuticals Inc. | 0.63 | 0.50 | 0.53 | — | — | |
Thermo Fisher Scientific Inc. | 0.41 | 0.47 | 0.44 | — | — | |
Vertex Pharmaceuticals Inc. | 0.56 | 0.53 | 0.50 | — | — | |
Total Asset Turnover, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | 0.45 | 0.39 | 0.40 | — | — | |
Total Asset Turnover, Industry | ||||||
Health Care | 0.76 | 0.70 | 0.71 | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Total asset turnover = Revenue ÷ Total assets
= 7,776 ÷ 13,900 = 0.56
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Zoetis Inc. total asset turnover ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 exceeding 2019 level. |
Equity Turnover
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Revenue | 7,776) | 6,675) | 6,260) | 5,825) | 5,307) | |
Total Zoetis Inc. equity | 4,543) | 3,769) | 2,708) | 2,185) | 1,770) | |
Long-term Activity Ratio | ||||||
Equity turnover1 | 1.71 | 1.77 | 2.31 | 2.67 | 3.00 | |
Benchmarks | ||||||
Equity Turnover, Competitors2 | ||||||
AbbVie Inc. | 3.65 | 3.50 | — | — | — | |
Amgen Inc. | 3.63 | 2.58 | 2.30 | — | — | |
Bristol-Myers Squibb Co. | 1.29 | 1.12 | 0.51 | — | — | |
Eli Lilly & Co. | 3.15 | 4.35 | 8.56 | — | — | |
Gilead Sciences Inc. | 1.28 | 1.34 | 0.98 | — | — | |
Johnson & Johnson | 1.27 | 1.31 | 1.38 | — | — | |
Merck & Co. Inc. | 1.28 | 1.90 | 1.81 | — | — | |
Pfizer Inc. | 1.05 | 0.66 | 0.82 | — | — | |
Regeneron Pharmaceuticals Inc. | 0.86 | 0.77 | 0.71 | — | — | |
Thermo Fisher Scientific Inc. | 0.96 | 0.93 | 0.86 | — | — | |
Vertex Pharmaceuticals Inc. | 0.75 | 0.71 | 0.68 | — | — | |
Equity Turnover, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | 1.35 | 1.31 | 1.26 | — | — | |
Equity Turnover, Industry | ||||||
Health Care | 2.10 | 2.06 | 2.06 | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Equity turnover = Revenue ÷ Total Zoetis Inc. equity
= 7,776 ÷ 4,543 = 1.71
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Zoetis Inc. equity turnover ratio deteriorated from 2019 to 2020 and from 2020 to 2021. |